Seeking Alpha nominates four companies that is says could be the next acquisition targets in the biotech arena. None of these names should come as a surprise to anyone. But, SA says these companies have strong pipelines offering good value and are sellingat a discount right now relative to their peers. That could mean a shopping opportunity for Big Pharma. The lucky four:
- Amgen (low P/E, high margins, and low price to book ratio)
- Athersys (rated as buy or outperform by all 5 analysts following the company)
- Biomarin (4 approved products, high profit margins and high current ratio, Citi Investment Research Top Mid Cap Buy)
- Celgene (EPS = 1.88, high profit margin, analyst backing)
Company acquisitions seem to be relatively active right now and there is plenty of money around within Big Pharma -- who are always looking to augment their relatively weak pipelines.
Posted by Bruce Lehr April 5th 2011.
Comments